American Journal of Obstetrics and Gynecology
SupplementPharmacokinetics of oseltamivir among pregnant and nonpregnant women
Section snippets
Materials and methods
Women were recruited from 3 clinical research centers in the Eunice Kennedy Shriver National Institute of Child Health and Human Development–sponsored Obstetric-Fetal Pharmacology Research Units Network. Sites include Magee-Women's Hospital of the University of Pittsburgh Medical Center, Pittsburgh, PA; University of Texas Medical Branch, Galveston, TX; and the University of Washington Medical Center, Seattle, WA. Pregnant subjects were recruited and enrolled during the 2009 influenza season
Results
A total of 26 pregnant women were approached for participation, and 22 underwent the informed consent process. Six pregnant women opted for nonparticipation for various reasons after undergoing informed consent procedures. There were no nonpregnant women who underwent informed consent who subsequently decided not to participate. Data from 16 pregnant women and 23 nonpregnant control women were available for analysis.
The demographic characteristics for the 2 study populations are listed in Table
Comment
This study demonstrates that exposure to oseltamivir carboxylate (active metabolite of oseltamivir) following oral administration of oseltamivir is decreased by approximately 30% during pregnancy compared to nonpregnant women of reproductive age. While the precise clinical implications of these findings are not completely understood, this information is important and could have a substantial impact on dosing recommendations and antiviral effectiveness in pregnant women with influenza. The PK
Acknowledgment
The study team acknowledges Roche Pharmaceuticals for sample analysis and logistic support.
References (28)
- et al.
Maternal mortality in the epidemic of Asian influenza, New York City, 1957
Am J Obstet Gynecol
(1958) - et al.
H1N1 2009 influenza virus infection during pregnancy in the USA
Lancet
(2009) - et al.
Safety and pharmacokinetics of oseltamivir at standard and high dosages
Int J Antimicrob Agents
(2010) Emergence of a novel swine-origin influenza A (H1N1) virus in humans
N Engl J Med
(2009)- et al.
Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008
MMWR Morb Mortal Wkly Rep
(2008) - et al.
Epidemic pneumonia (Spanish influenza) in pregnancy: effect in one hundred and one cases
JAMA
(1918) Pandemic influenza and pregnancy: a call for preparedness planning
Obstet Gynecol
(2007)- et al.
Impact of influenza on acute cardiopulmonary hospitalizations in pregnant women
Am J Epidemiol
(1998) - et al.
Influenza virus infection in the second and third trimesters of pregnancy: a clinical and seroepidemiological study
Br J Obstet Gynaecol
(2000) - et al.
Hospitalizations with respiratory illness among pregnant women during influenza season
Obstet Gynecol
(2006)
Severe 2009 H1N1 influenza in pregnant and postpartum women in California
N Engl J Med
2009 H1N1 influenza A and pregnancy outcomes in Victoria, Australia
Clin Infect Dis
Safety of neuraminidase inhibitors against novel influenza A (H1N1) in pregnant and breastfeeding women
CMAJ
Pandemic influenza and pregnant women
Emerg Infect Dis
Cited by (73)
Drug development research in pregnant and lactating women
2021, American Journal of Obstetrics and GynecologyClinical pharmacology of anti-infectives during pregnancy
2021, Clinical Pharmacology During PregnancyIntroduction
2021, Clinical Pharmacology During PregnancyPharmacokinetics of oseltamivir phosphate and oseltamivir carboxylate in non-pregnant and pregnant rhesus monkeys
2020, Regulatory Toxicology and PharmacologyCitation Excerpt :A shortcoming of this study was the lack of pharmacokinetic data in non-pregnant women. Beigi et al., 2011 reported pharmacokinetic data for 16 pregnant women (three in Trimester 1, nine in Trimester 2, and four in Trimester 3) compared to 23 non-pregnant women. The reported pharmacokinetic parameters for oseltamivir (AUC0-∞, CL, Vd, and t1/2) did not differ between pregnant and non-pregnant women, while the AUC0-∞ for oseltamivir carboxylate was significantly smaller in pregnant women and the CL was significantly greater.
Current antiviral drugs and their analysis in biological materials—Part I: Antivirals against respiratory and herpes viruses
2018, Journal of Pharmaceutical and Biomedical AnalysisCitation Excerpt :They were also properly validated and have determined matrix effects using post-column addition or post-extraction addition approach. However, several methods were used for clinical purposes without thorough method validation [92,103,111] or without the determination of matrix effects although MS/MS was used for detection [107]. Antiviral drugs are very complex and challenging drug family.
Reprints not available from the authors.
Conflict of Interest: This work was supported by grants from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (HD047905, HD047891, HD047892) and by the Office of Research on Women's Health, National Institutes of Health (NIH). Dr Mattison was supported by funds from the intramural program of NICHD, NIH. In addition, this work was supported in part by Grant no. UL1RR025014 from the NIH National Center for Research Resources. Drs Beigi, Han, Venkataramanan, Hankins, Clark, Hebert, Easterling, Zajicek, Ren, and Caritis have no conflicts to report.
The contents of this article are the views of the authors and do not necessarily represent the official view of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, Office of Research on Women's Health, or National Institutes of Health.
Publication of this article was supported by the Centers for Disease Control and Prevention and the Association of Maternal and Child Health Programs.